Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina FDA Decision: Century Therapeutics, Inc. (IPSC)

The Phase 2 date for Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina by Century Therapeutics, Inc. (IPSC) is scheduled for June 9, 2032. This is the target date for the FDA to make a decision on this application.

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina is being developed by Century Therapeutics, Inc. for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina receives FDA approval, Century Therapeutics, Inc. (IPSC) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IPSC on DilutionWatch at dilutionwatch.com/stock/IPSC.html.

You can view the full BiotechSigns company profile for Century Therapeutics, Inc. (IPSC) at biotechsign.com/app/company/IPSC, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.